{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:51:49Z","timestamp":1740142309231,"version":"3.37.3"},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["VHRM"],"DOI":"10.2147\/vhrm.s133690","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T21:35:22Z","timestamp":1499376922000},"page":"247-253","source":"Crossref","is-referenced-by-count":2,"title":["Eligibility for alirocumab or evolocumab treatment in 1090 hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ≥70 mg\/dL despite maximal-tolerated LDL-cholesterol-lowering therapy"],"prefix":"10.2147","volume":"Volume 13","author":[{"given":"Vybhav","family":"Jetty","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Glueck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naila","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marloe","family":"Prince","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3428-3566","authenticated-orcid":false,"given":"Michael","family":"Goldenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4333-1614","authenticated-orcid":false,"given":"Ishan","family":"Anand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2017,7]]},"container-title":["Vascular Health and Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=37309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=37309","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T21:35:23Z","timestamp":1499376923000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/eligibility-for-alirocumab-or-evolocumab-treatment-in-1090-hypercholes-peer-reviewed-article-VHRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/vhrm.s133690","relation":{},"ISSN":["1178-2048"],"issn-type":[{"type":"electronic","value":"1178-2048"}],"subject":[],"published":{"date-parts":[[2017,7]]}}}